9/27/2010 8:19:35 AM
BEDFORD, Mass., Sept. 23 /PRNewswire/ -- Instrumentation Laboratory (IL), today announced it will host the 2nd IL Asia Pacific Hemostasis Forum on Wednesday, October 13, 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. The event will run from 8:00 am to 12:00 pm, local time. The forum will focus on the latest clinical and diagnostic advances and trends in hemostasis. All healthcare professionals, practicing in the Asia Pacific region are welcome to attend.
Professor Karmel Tambunan, MD, PhD, from the Division of Hematology and Medical Oncology at the University of Indonesia, Jakarta will serve as Scientific Chairman of the Forum. In addition, several prominent experts in the field will present key information and lead discussions during the Forum, including Professor Ismail Elalamy, MD, a Hematologist at the Hopital Tenon, Paris France; Associate Professor Tatsuya Atsumi, MD, PhD, from the Graduate School of Medicine at Hokkaido University, Sapporo, Japan; and, Associate Professor Chris Ward, from the Department of Haemotology and Transfusion Medicine at the Royal North Shore Hospital, Sydney, Australia.
Topics will include new approaches and developments in the diagnosis of Heparin-Induced Thrombocytopenia (HIT), as well as new and emerging markers for Antiphospholipid Syndrome (APS) and associated clinical challenges.
"We are so honored to have some of the leading clinicians from around the world sharing their expertise on HIT and APS management and diagnostics," said Santiago Ramos, Regional Manager for North East Asia. "The Forum will address many of the key issues facing clinicians today and will provide new information to help them deliver the very best patient care."
HIT is a severe immune reaction to Heparin that can result in the paradoxical development of a thrombotic event. One of the most common of all adverse drug effects, due to the sheer volume of patients receiving Heparin therapy (over 12 million patientsannually in the US alone), it has a significant impact on anticoagulant management in hospitals worldwide. If left untreated, patients with HIT may develop serious sequelae, including pulmonary embolism, myocardial infarction, or death.
Registering to Attend
Through October 1st, 2010, individuals can register to attend this Forum, by contacting Carol Lee, at firstname.lastname@example.org
Karmel Tambunan, MD, PhD
Dr. Tambunan is a Professor of Clinical Medicine, Division Hematology-Medical Oncology, at the University of Indonesia, Cipto Mangunkusumo Hospital. He is a board-certified Internist, and a Fellow of the Academy of Clinical and Applied Thrombosis and Hemostasis. Dr. Tambunan is a member of several Advisory Boards for the Asian Pacific region including those focused on Venous Thromboembolism, Myeloproliferative Disorders and Idiopathic Thrombocytopenia Purpura. He has participated in several international research studies, and is a reviewer for the Annals of Oncology.
Ismail Elalamy, MD, PhD
Dr. Elalamy is Professor of Hematology and Director of Hematology, Department of Thrombosis Center, at the Hopital Tenon in Paris, France.
Tatsuya Atsumi, MD, PhD
Dr. Atsumi is Associate Professor, Department of Medicine at Hokkaido University Graduate School of Medicine, in Sapporo, Japan. He is also a Consultant Rheumatologist. He is a graduate of Hokkaido University, and completed his research fellowship in the Lupus Unit at St Thomas' Hospital, in London, England.
Christopher Ward, PhD, MBChB, BMedSc
Dr. Ward is an Associate Professor and Clinical Haematologist, Department of Haematology and Transfusion Medicine at Royal North Shore (RNS) Hospital in Australia. His research focuses on coagulation and vascular biology. Additionally, he is the Director of the Northern Blood Research Centre, supervising research in platelet function, hypercoagulability in cancer and other disease states, and global tests of coagulation. Dr. Ward is the lead investigator for clinical trials of new anticoagulants and thrombopoietin agonists at RNS. He was President of the Australasian Society for Thrombosis and Haemostasis from 2007-2009 and represented the Royal Australasian College of Physicians on a national advisory panel, developing the 2009 NHMRC Clinical Practice Guideline on venous thrombosis prevention in Australian hospitals.
Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM® product offerings, part of the critical care line, include the new GEM Premier 3500 with Intelligent Quality Management (iQM®), GEM Premier 4000 analyzer, GEMweb Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer. IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the new ACL TOP 700, the new ACL TOP 700 LAS and the ACL TOP 500 CTS. IL also offers the new ACL AcuStar, ACL ELITE® and ELITE PRO, other hemostasis analyzers and the HemosIL® line of reagents, including HIT-Ab(PF4-H). IL is based in Bedford, Massachusetts.
The Instrumentation Laboratory logo and HemosIL are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.
SOURCE Instrumentation Laboratory